CSF biomarkers for mild cognitive impairment
- 20 August 2004
- journal article
- review article
- Published by Wiley in Journal of Internal Medicine
- Vol. 256 (3) , 224-234
- https://doi.org/10.1111/j.1365-2796.2004.01368.x
Abstract
A correct clinical diagnosis of Alzheimer's disease (AD) early in the course of the disease is of importance to initiate symptomatic treatment with acetylcholine esterase inhibitors, and will be even more important when disease-arresting drugs, such as beta-sheet breakers or gamma-secretase inhibitors, will reach the clinic. However, there is no clinical method to determine if a patient with mild cognitive impairment (MCI) has incipient AD, i.e. will progress to AD with dementia, or have a benign form of MCI without progression. Thus, there is a great clinical need for diagnostic biomarkers to identify incipient AD in MCI cases. Three cerebrospinal fluid (CSF) biomarkers; total-tau (T-tau), phospho-tau (P-tau) and the 42 amino acid form of beta-amyloid (Abeta42) have been evaluated in numerous scientific papers. These CSF markers have high sensitivity to differentiate early and incipient AD from normal ageing, depression, alcohol dementia and Parkinson's disease, but lower specificity against other dementias, such as frontotemporal and Lewy body dementia. However, if the CSF biomarkers are used in the right clinical context, i.e. together with the cumulative information from the clinical examination, standard laboratory tests and brain-imaging techniques [single photon emission tomography (SPECT) and magnetic resonance tomography (MRT) scans], they may have a role in the clinical evaluation of MCI cases.Keywords
This publication has 100 references indexed in Scilit:
- Differentiation of Geriatric Major Depression From Alzheimer’s Disease With CSF Tau Protein Phosphorylated at Threonine 231American Journal of Psychiatry, 2003
- Cerebrospinal fluid Aβ42 is reduced in multiple system atrophy but normal in Parkinson's disease and progressive supranuclear palsyMovement Disorders, 2002
- Cerebrospinal Fluid Amyloid β1–42 Levels in the Mild Cognitive Impairment Stage of Alzheimer's DiseaseExperimental Neurology, 2001
- Primary Degenerative Mild Cognitive Impairment: Study Population, Clinical, Brain Imaging and Biochemical FindingsDementia and Geriatric Cognitive Disorders, 2001
- The Cerebrospinal Fluid Levels of Tau, Growth-Associated Protein-43 and Soluble Amyloid Precursor Protein Correlate in Alzheimer’s Disease, Reflecting a Common Pathophysiological ProcessDementia and Geriatric Cognitive Disorders, 2001
- Age-Dependent Change in the Levels of Aβ40 and Aβ42 in Cerebrospinal Fluid from Control Subjects, and a Decrease in the Ratio of Aβ42 to Aβ40 Level in Cerebrospinal Fluid from Alzheimer’s Disease PatientsEuropean Neurology, 2000
- Biochemical Evidence for the Long-Tail Form (Aβ1-42/43) of Amyloid β Protein as a Seed Molecule in Cerebral Deposits of Alzheimer′s DiseaseBiochemical and Biophysical Research Communications, 1994
- Soluble Amyloid β-Protein Is a Marker of Alzheimer Amyloid in Brain But Not in Cerebrospinal FluidBiochemical and Biophysical Research Communications, 1994
- The carboxy terminus of the .beta. amyloid protein is critical for the seeding of amyloid formation: Implications for the pathogenesis of Alzheimer's diseaseBiochemistry, 1993
- Clinical diagnosis of Alzheimer's diseaseNeurology, 1984